Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
About This Webcast
Phio Pharmaceuticals is a clinical stage biotechnology company co-founded by the scientist who was awarded the Nobel prize in 2006 for his discovery of RNAi. RNAi is precision targeted immuno-oncology therapy which has broad applications, across multiple cell types. Phio’s proprietary siRNA platform INTASYL®, derived from RNAi is the only self-delivering siRNA focused on immuno-oncology therapeutics. Book a Meeting With This Company (opens in a new tab) Industry: Clinical-stage immuno-oncology biotechnology for this company (opens in a new tab) Visit Investor Relations Website for this company (opens in a new tab) Connect on LinkedIn with this company (opens in a new tab) Follow on X this company (opens in a new tab)
Speakers
Robert Bitterman
President & CEO , Phio Pharmaceuticals Corp.
Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as our President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.